Report Materials
Generic drug price increases exceeded the specified
statutory inflation factor applicable to brand-name drugs for 35 percent of the
quarterly average manufacturer prices reviewed. If the provision for brand-name
drugs were extended to generic drugs, the Medicaid program would receive
additional rebates. By applying the method in the Social Security Act for
calculating additional rebates on brand-name drugs to generic drugs
we calculated that the Medicaid program would have received a total of $966
million in additional rebates for the top 200 generic drugs, ranked by Medicaid
reimbursement, from 1991 through 2004.
We recommended that the Centers for Medicare & Medicaid Services (CMS) consider seeking legislative authority to extend the
additional rebate provisions to generic drugs. CMS agreed to consider the
recommendation when it considers future legislative proposals.
Notice
This report may be subject to section 5274 of the National Defense Authorization Act Fiscal Year 2023, 117 Pub. L. 263.